UPDATE 2-Alnylam's gene-silencing efforts get $2 bln Blackstone backing
April 13, 2020 at 11:31 AM EDT
Blackstone Group Inc said on Monday it would invest $2 billion in Alnylam Pharmaceuticals Inc through an equity-and-debt deal, giving the drugmaker a financial boost without tapping into currently volatile stock markets for funds.
